<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Indraprastha Medical Corporation Ltd on Financial Report Insights</title>
    <link>https://reports.muthu.co/tags/indraprastha-medical-corporation-ltd/</link>
    <description>Recent content in Indraprastha Medical Corporation Ltd on Financial Report Insights</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Tue, 17 Sep 2024 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://reports.muthu.co/tags/indraprastha-medical-corporation-ltd/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Indraprastha Medical Corporation Ltd - Annual Report 2023-24 Analysis</title>
      <link>https://reports.muthu.co/posts/indraprastha-medical-corporation-ltd/</link>
      <pubDate>Tue, 17 Sep 2024 00:00:00 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/indraprastha-medical-corporation-ltd/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;overview&#34;&gt;&#xA;  Overview&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#overview&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;detailed-analysis&#34;&gt;&#xA;  Detailed Analysis&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#detailed-analysis&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;p&gt;This analysis examines the Indraprastha Medical Corporation Limited (IMCL) annual report for FY2023-2024, focusing on financial performance, business segments, risks, and ESG (Environmental, Social, and Governance) initiatives.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;I. Financial Performance:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;The report highlights strong financial growth in FY2023-2024 compared to FY2022-2023:&lt;/p&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Income from Operations:&lt;/strong&gt; Increased by 13% to Rs. 1244.7 crore from Rs. 1098.67 crore.  This growth is attributed to a 3% increase in discharges and a 10% increase in revenue per patient. Revenue per bed day also saw a 13% increase, indicating improved operational efficiency.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Profit Before Tax (PBT):&lt;/strong&gt;  Increased significantly by 42% to Rs. 166.11 crore from Rs. 117.18 crore.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Profit After Tax (PAT):&lt;/strong&gt;  Increased by 44% to Rs. 123.96 crore from Rs. 86.15 crore.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Earnings Per Share (EPS):&lt;/strong&gt; Increased by 44% to Rs. 13.52 from Rs. 9.4.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Dividend:&lt;/strong&gt; The board recommended a dividend of Rs. 4.50 per equity share (45%), totaling Rs. 41.25 crore, subject to shareholder approval.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Key Financial Ratios:&lt;/strong&gt;&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
